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Abstract 31 
 32 
Robotic assisted radical cystectomy (RARC) has been adopted widely in many centres, owed largely to the success 33 
of robotic assisted laparoscopic prostatectomy (RALP). It aims to replicate the oncological outcomes of open radical 34 
cystectomy (ORC), while providing a shorter recovery period. Despite this, previous RCTs have failed to show a 35 
benefit for RARC over ORC. These trials have compared extracorporeal RARC (eRARC) to ORC, which requires a 36 
further incision to mobilise the bowel for urinary reconstruction with an open technique. For intracorporeal RARC 37 
(iRARC), this urinary reconstruction is performed robotically without further incisions. There are theoretical 38 
benefits to this approach such as reduced recovery time for the bowel and reduced ileus rates, but no level 1 39 
evidence currently exists to support this. While there has been an improvement in patient outcomes since the 40 
adoption of RARC, various other factors, such as enhanced recovery programmes and surgical learning curve, have 41 
made it difficult to attribute this solely to the robotic approach as many centres performing ORC have also shown 42 
similar improvements. In this review, we will discuss implementation of RARC as well as peri-operative measures 43 
that have helped improve outcomes, offer a comparison of outcomes between ORC and RARC, and highlight 44 
upcoming RCTs that may offer new evidence for or against a paradigm shift in the future of bladder cancer surgery.  45 
 46 
Keywords: Robotic cystectomy; intracorporeal; extracorporeal; bladder cancer; enhanced recovery  47 
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Introduction 48 
With the increased use of robotics in the operating theatre, robot-assisted radical cystectomy (RARC) has been 49 
adopted by many high volume tertiary centres as standard treatment. This has been supported by evidence of 50 
oncologic equivalence[1,2], and possible benefits of faster recovery, shorter lengths of hospital stay and a quicker 51 
return to normal activities when compared with its open counterpart. Open radical cystectomy (ORC) has 52 
traditionally been considered the gold standard treatment for muscle-invasive bladder cancer, but as with other 53 
surgical procedures, laparoscopic adaptations of the procedure such as laparoscopic radical cystectomy (LRC) and 54 
RARC have gained traction. Radical cystectomy has a high attrition rate from the disease process. Nearly 50% of 55 
patients have a metastatic recurrence within five years of surgery[3], and most of these patients subsequently die 56 
from the disease. Open cystectomy has a 5.1%[4] risk of mortality, and 90-day complication rates of up to 64.4%[5]. 57 
With increased costs of surgery due to adoption of RARC, health economics of adopting this approach will require 58 
an improvement in the outcomes compared to ORC[6] and LRC[7].  59 
 60 
The first laparoscopic cystectomy was performed in 1992[8], although this was a simple cystectomy without 61 
lymphadenectomy for pyocystis and not bladder cancer. Sánchez de Badajoz et al.,[9] then described an LRC on a 62 
patient with muscle-invasive bladder cancer. With the arrival of the da Vinci system in 2001, there has been a lot of 63 
interest to replicate the principles and successes of LRC in RARC. 64 
This has been a largely successful endeavour, with multiple randomized controlled trials and meta-analyses 65 
reporting equivalence in both oncologic and 90-day outcomes[10,11].  66 
 67 
There are two main techniques used for urinary diversion during RARC, 1) extracorporeal urinary diversion 68 
(eRARC) and 2) intracorporeal urinary diversion (iRARC). Extracorporeal diversion involves an extra 5 to 7 cm 69 
skin incision[12] (muscle splitting incision in the right iliac fossa for an ileal conduit and lower midline incision for 70 
an orthotopic neobladder) to bring out the intestine following completion of the cystectomy. Intracorporeal diversion 71 
has additional potential benefits including less incisional pain, decreased bowel exposure and desiccation, and the 72 
potential for decreased fluid imbalances[13]. 73 
 74 
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In the evolution of practice in our centre, we have moved from ORC to iRARC. One surgeon did perform 3 75 
extracorporeal robotic assisted cystectomies (eRARC) before adopting iRARC, whereas the other switched directly 76 
from ORC to iRARC. Enhanced recovery has only been introduced in our centre in the last 16 months, but has 77 
provided significant additional improvement in various outcomes. 78 
 79 
In this review, we will explore the role of robotics in the management of bladder cancer, with an emphasis on 80 
optimisation of the patient pathway, complications, outcomes and the future of robotics in the management of 81 
bladder cancer. 82 
 83 
Preoperative optimisation 84 
 85 
In our centre, the clinical pathway is set up to have a one-stop multidisciplinary team (MDT) assessment clinic, 86 
where patients have appointments with their urologist, anaesthetist, enhanced recovery team, urinary diversion team, 87 
pre-assessment and cardiopulmonary exercise testing (CPET). CPET is part of our local pre-operative investigations, 88 
as it can provide an objective measure of physiological reserve under stress, and can be used to stratify perioperative 89 
risk, identify the need for pre-operative optimisation and pre-empt post-operative complications. Our local 90 
experience suggests that patients with poor cardio-pulmonary reserve and patients with pre-operative anaemia 91 
undergoing iRARC have better outcomes and recovery in comparison with ORC[14,15]. 92 
 93 
On the day of cystectomy, patients are permitted solid food until six hours prior to surgery, and clear fluids up to 94 
two hours prior to surgery. Patients are also provided high-calorie carbohydrate drinks to have the night before 95 
surgery and the morning of surgery to minimise insulin resistance and catabolism of non-carbohydrate products due 96 
to surgical stress[16]. Carbohydrate loading has been proven to reduce length of stay and early return to normal 97 
bowel function in an RCT setting for colorectal surgical patients[17].  98 
Intra-operative measures 99 
 100 
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The patient is placed on a green foam non-slip mattress upon arrival in theatre. The skin around the incision sites is 101 
shaved and cleaned with chlorhexidine. Intravenous broad spectrum antibiotics (cefuroxime, metronidazole and 102 
gentamicin) are given intra-operatively, and continued for a further 24 hours post-operatively to reduce the risk of 103 
post-operative infections of the wounds as well as any potential bowel content spillage. If bowel content spillage is 104 
identified intra-operatively, the antibiotic regimen is continued for five days. 105 
 106 
A nasogastric tube is inserted under anaesthetic to deflate the stomach, and a urinary catheter is inserted to drain the 107 
urinary bladder. The Bair Hugger (3M, St Paul, MN, USA) device is used to maintain a temperature above 36 108 
degrees Celsius. 109 
 110 
Spinal analgesia with a dose of 1.5-2ml 0.5% heavy bupivacaine + 1mg diamorphine is used as standard in 111 
conjunction with general anaesthesia. In addition to standard Association of Anaesthetists of Great Britain & Ireland 112 
(AAGBI) invasive arterial and entropy monitoring is used to balance anaesthesia. Fluid replacement is optimised 113 
using goal directed fluid therapy monitoring 114 
 115 
The patient is positioned in a steep Trendelenburg position, with arms adducted to the sides and padding on all 116 
possible pressure points. Intravenous paracetamol and lidocaine (2 mg/kg/hour for the duration of the operation) are 117 
given for analgesia at the start of surgery, with the addition of diclofenac if the patient has good kidney function 118 
(eGFR > 60). The use of IV lidocaine was first adopted for laparoscopic colectomy, and has been shown to reduce 119 
the need for post-operative analgesia, opioid use and length of hospital stay, as well as to accelerate post-operative 120 
bowel function[18]. 121 
Post-operative measures and the role of enhanced recovery after surgery 122 
(ERAS) 123 
Using a neuraxial block allows for some advantages over epidural anaesthesia as side effects such as hypotension 124 
and motor block are not encountered. It also enables early mobilisation as the patient is not continuously connected 125 
to an infusion pump[19].  126 
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 127 
The nasogastric tube is removed prior to waking the patient up and all patients go to the high dependency unit for 128 
overnight optimisation postoperatively. 129 
 130 
Intermittent pneumatic compression in theatre, compression stockings and subcutaneous low molecular weight 131 
heparin are used as standard practice for all patients undergoing cystectomy as part of venous thromboembolism 132 
prophylaxis. The first dose is given within six hours post-operatively, and once daily thereafter for four weeks post-133 
operatively.  134 
 135 
The implementation of enhanced recovery after surgery (ERAS) pathways including routine use of epidural or spinal 136 
analgesia, antimicrobial prophylaxis, standard anaesthetic protocols, preventing intraoperative hypothermia, early 137 
ambulation and early nasogastric tube removal has led to a reduction in time to tolerating oral diet without 138 
worsening morbidity[20]. The ERAS programme was first implemented in colorectal surgery, with a reduction in 139 
length of stay and complication rates, with no significant difference in readmission and mortality rates[21]. 140 
 141 
ERAS pathways have been widely adopted, and have shown some success in improving outcomes for RARC, as 142 
well as ORC.  Julian et al., reported their experience in Southampton for ORC and found that the implementation of 143 
an ERAS programme resulted in multiple marginal gains, which led to a significant decrease in median length of 144 
stay from 14 days to 7 days[22]. The implementation of the ERAS programme for iRARC in our centre has also 145 
significantly reduced the length of hospital stay and a reduction in morbidity[23]. The median length of stay in our 146 
centre has reduced from 17 days with ORC to 10 days with iRARC, and a further reduction to 7 days with the 147 
implementation of ERAS alongside iRARC. While this effect is largely attributed to the ERAS programme itself, it 148 
must be recognised that the surgeons were further along their learning curve for these cases, and this could have 149 
contributed to the faster recovery and discharge of patients. 150 
 151 
The EAU Robotic Urology Section Scientific Working Group Consensus review found that there is a lack of high-152 
level evidence[24] for ERAS in patients undergoing RARC, but that it is difficult to assess the multimodal nature of 153 
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such programmes through RCTs. The consensus recommends a standardised enhanced recovery programme specific 154 
to patients undergoing RARC, and this has been used as a template for adoption by various centres including ours. 155 
 156 
Our local set up process for ERAS involved an initial assessment of local data, implementing improvements and 157 
analysing the marginal gains in various domain. Various tools are instrumental to the adoption of the ERAS 158 
programme, such as stakeholder analysis, process compliance auditing, PDSA (Plan, Do, Study, Act) cycles etc. 159 
Various resources such as e-LfH (eLearning for Healthcare)[25] and PRISM (perioperative improvement science 160 
and management)[26] provide guidance for quality improvement methodology to use these tools optimally. 161 
Outcomes 162 
90-day complications 163 
In a systematic review of the literature, Novara et al.[11], identified 105 articles describing outcomes of RARC 164 
(both iRARC and eRARC) vs ORC. In the meta-analysis of this data, they concluded that RARC, both 165 
intracorporeal and extracorporeal, can be performed safely within acceptable operative time, lower blood loss and 166 
transfusion rates. The risk of intraoperative complications is low, but post-operative complications are similarly high 167 
to ORC, with high grade complications of 33% at 90 days. Overall, they concluded that blood loss and hospital stay 168 
was better with RARC, and low-grade complications were lower for RARC but high grade complications were 169 
similar to ORC.  170 
 171 
However, in a systematic review of only the randomized controlled trials comparing eRARC vs ORC[10], Tan et al., 172 
found that while RARC is associated with lower estimated blood loss, transfusion requirement and wound related 173 
complications, there was no significant difference between groups in perioperative morbidity, length of stay, 174 
positive surgical margin rate, lymph node yield and lymph node positive. There have been four RCTs comparing 175 
eRARC vs ORC to date, and all of them did not show any significant difference in complications, but did establish 176 
non-inferiority of eRARC to ORC. 177 
 178 
Most 90-day major complications are related to surgical technical complications such as urinary leak, anastomotic 179 
stricture, significant bleeding, herniation and wound dehiscence[27]. For experienced surgeons, risk of urinary leak 180 
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is similar to ORC, and these leaks can be managed conservatively.  The International Robotic Cystectomy 181 
Consortium reported the 30-day and 90-day outcomes of 939 patients undergoing RARC, and 53 patients from this 182 
group returned to the operating theatre. The common reasons for re-operating were fascial dehiscence (n = 12), 183 
small bowel obstruction (SBO) or partial SBO (n = 8), urine leak (n = 7), and bleeding (n = 5).  184 
 185 
Furthermore, a volume-outcome relationship has been identified with radical cystectomy and other high-risk 186 
operations, where higher surgical volume can reduce mortality by up to 37%[28]. Combined with the high cost of 187 
robotic surgery, this has resulted in a shift towards centralization and consolidation of cancer services[29] in an 188 
effort to improve outcomes. 189 
 190 
Late complications 191 
Late complications can include some early complications such as urinary leak and strictures. Other complications 192 
that can occur after 90 days include incisional hernias, uretero-ileal stenosis, small bowel obstruction, febrile UTIs, 193 
sub-neovesical obstruction, metabolic complications, incontinence and retention[23]. 194 
 195 
Due to RARC being a relatively new procedure, long term complication data is not well-described in the literature as 196 
most studies describe complications up to 90 days. In a survey of 406 patients with a median of 27 months follow-197 
up, 23% (92) patients required surgical intervention after eRARC[30]. Re-operation rate was 5%, 2% and 16% at 31, 198 
31-90 and greater than 90 days respectively. Of these, uretero-ileal complications were the most common (48 cases), 199 
followed by interventions for bowel obstruction, fistulas and abdominal wall related complications. For comparison, 200 
a large series of 923 patients undergoing ORC by Hautmann et al., long-term complication rate was 40.8%[31]. 201 
 202 
Functional outcomes 203 
Functional measures such as urinary continence and quality of life are greatly relevant to patients undergoing 204 
cystectomy with neobladder formation. Continence rates tend to improve as time from surgery increases, and 205 
continence can continue to improve over a period of a few years. For instance, daytime continence increased from 206 
59% at less than 3 months postoperatively to 92% by 12 to 18 months[32],  and night-time continence rates of 75% 207 
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at 12 months improved to 94% at 3 years in ORC[33]. A systematic review of the literature found that in RARC, 12-208 
month continence rates with continent diversion were 83–100% in men for daytime continence and 66–76% for 209 
night-time continence, but they commented that very limited data was available for functional outcomes. This 210 
variance is likely to be related to surgeons being on their learning curve. A similar trend was observed initially for 211 
robotically-assisted radical prostatectomy (RALP) when compared to open prostatectomy, but continence rates are 212 
now similar for both procedures among experienced surgeons[34]. 213 
 214 
Post-operative quality of life is being recognised as an important outcomes measure following major surgery, and 215 
the health-related quality of life (HRQoL) measures have gained traction. Messer et al., performed an RCT 216 
evaluating HRQoL for ORC vs eRARC using the Functional Assessment of Cancer Therapy-Vanderbilt Cystectomy 217 
Index questionnaire[35]. They found that there were no significant differences between HRQoL outcomes between 218 
ORC and eRARC, with a return of quality of life scores to baseline 3 months after surgery in both cohorts, with a 219 
slightly higher physical well-being score in the RARC group at 6 months. This was a relatively small study of 47 220 
patients, but HRQoL is being measured in an ongoing trial in a randomised setting[36]. 221 
 222 
Oncological outcomes 223 
There is no level one evidence comparing oncological outcomes between RARC and ORC. However, various 224 
observational studies have reported similar outcomes[2,37,38] for RARC when compared to ORC. Lymph node 225 
yield is considered a surrogate for quality of surgery, and in RARC it has been comparable to ORC[2,39], with some 226 
studies reporting higher lymph node yield[40] in RARC compared to ORC. Following RARC, port-site metastases 227 
have been reported[41], but this is similar to surgical site metastases following ORC[42]. From the results of the 228 
International Robotic Cystectomy Consortium, 5-year disease-free survival, cancer-specific survival and overall 229 
survival rates following RARC are 67%, 75% and 50% respectively[43]. 230 
iRARC vs eRARC 231 
While the extirpative component (radical cystectomy and lymphadenectomy) is performed robotically in both 232 
eRARC and iRARC, the difference is in the reconstructive component (urinary diversion). This is performed by 233 
open surgery in eRARC while being done completely intracorporeally in iRARC. An interesting hypothesis is that 234 
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physiological stress response associated with minimally invasive cystectomy and intracorporeal reconstruction 235 
would be less than that of extracorporeal reconstruction or open surgery. 236 
 237 
The four RCTs comparing RARC vs ORC have all used eRARC for their reconstruction of the bladder, and as 238 
previously mentioned, these RCTs failed to show any significant difference. It has been established that iRARC is 239 
feasible with good complication rates, comparable early oncological outcomes[44] and similar recurrence patterns to 240 
ORC. To our knowledge, there have been no RCTs comparing intracorporeal reconstruction (iRARC) with either 241 
ORC or eRARC. Observational data has been used to compare outcomes of iRARC, and 90-day outcomes were 242 
found to be similar to that of eRARC, with a non-significant trend in 90-day complication rate favouring iRARC 243 
(41% vs 49%, p = 0.05)[45]. However, it is difficult to draw conclusions from retrospective observational data, and 244 
high quality level 1 and level 2 evidence is required to compare the two techniques. 245 
Learning curve 246 
There is no accepted definition of what constitutes an experienced surgeon for RARC. For comparison, the 247 
definition of proficient surgeon for RALP varies from having performed between 20 to 250 cases[46–48]. Relatively 248 
few publications in the literature have explored the nature of the learning curve and its effect on outcomes. Hayn et 249 
al., used operative time, estimated blood loss, lymph node yield and positive surgical models, and estimated that 21 250 
patients were required for operative time to reach 6.5h and 8, 20, and 30 patients were required to reach an LNY of 251 
12, 16, and 20, respectively[49]. Richards et al., found that complications decreased as the learning curve progressed 252 
from 14 (70%) in the 1st tertile to 6 (30%) in each of the 2nd and 3rd tertiles, mean total operative time trended 253 
down from the 1st to 3rd tertile from 525 minutes to 449 minutes but the blood loss was unchanged[50]. 254 
 255 
 The Pasadena Consensus Panel recommends that a surgeon’s initial learning curve is the first 20-30 cases, and they 256 
should be supervised by an experienced mentor with a reduced focus on operative time, and avoiding complex 257 
patients (bulky tumours, obese patients, patients with previous radiotherapy, surgery or adhesions). For the next 258 
approximately 70 cases, the surgeon should focus on reducing operative time, blood loss and starting building on 259 
intracorporeal reconstruction experience. After a total of 100 cases, the surgeon is considered very experienced and 260 
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should take on more challenging cases. Particularly at the early stages of the learning curve, surgeons should have a 261 
low threshold for converting to ORC[51].  262 
Ongoing trials 263 
As discussed previously, observational data suggests that oncological outcomes of RARC are non-inferior to ORC, 264 
but this has not been reported in a trial setting. The randomized open vs open cystectomy (RAZOR) is a multi-centre 265 
RCT to compare oncological outcomes of eRARC vs ORC at 15 centres, with a primary endpoint 2-year progression 266 
free survival[36]. As of February 2015, 306 patients had been recruited (total expected recruitment of 320 patients), 267 
and results of the study are expected in 2017. 268 
 269 
No previous RCTs have compared iRARC to either techniques in a trial setting. The intracorporeal Robotic vs Open 270 
Cystectomy (iROC) trial[52] is a multi-centre RCT in the UK to compare 90-day outcomes between iRARC and 271 
ORC. It has started recruitment in March 2017 and aims to recruit 320 patients, with a primary endpoint of days 272 
alive and out of hospital at 90 days[53]. Where previous trials have shown non-inferiority of eRARC to ORC, the 273 
iROC trial will be the first trial to attempt to compare iRARC performed by experienced surgeons (>30 cases) 274 
versus ORC performed by similarly experienced surgeons. 275 
Conclusions 276 
Over the last 15 years, there have been various improvements in the instruments, techniques and surgeon expertise 277 
in robotic uro-oncology. While complications are common after RARC, current data suggests that complication 278 
rates are similar to ORC. With expert consensus on peri-operative care, it is important to understand the impact of 279 
enhanced recovery programmes on patient care. The constant evolution of methods and improvements in peri-280 
operative tools such as enhanced recovery programmes have confounded the assessment of the true advantages of 281 
robotics in the context of bladder cancer. 282 
 283 
As surgeons become experienced or even expert at RARC, we eagerly await the results of ongoing trials in the 284 
modern setting to answer a very important question: is there going to be a new gold standard in radical treatment of 285 
bladder cancer? 286 
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